Melatonin Attenuates Cardiac Ischemia-Reperfusion Injury through Modulation of IP3R-Mediated Mitochondria-ER Contact

Wenya Li, Botao Liu, Lin Wang, Jilie Liu, Xiuhui Yang, and Jia Zheng

1Department of Cardiology, Luohe Central Hospital, Luohe Medical College, 56# Renmin Ave, Luohe 462000, China
2Department of Hypertension, Luohe Central Hospital, Luohe Medical College, 56# Renmin Ave., Luohe 462000, China
3Department of Cardiology, Tianjin First Central Hospital, 24 Fukang Road, Nankai District, Tianjin 300192, China

Correspondence should be addressed to Jia Zheng; zhengjia2255@126.com

Received 23 June 2021; Revised 17 July 2021; Accepted 24 July 2021; Published 10 August 2021

1. Introduction
Reperfusion strategies such as internal thrombolysis and surgery are used for the clinical management of patients with acute coronary syndrome (ACS) to salvage the damaged myocardium [1–3]. However, after sustained myocardial ischemia, reperfusion is also associated with additional damage to the myocardium, a phenomenon called myocardial postischemic reperfusion (I/R) damage [4–6]. Indeed, myocardial reperfusion damage is a condition initiated at the stage of ischemia and amplified during the reperfusion period [7, 8]. Although several approaches can effectively treat myocardial ischemia, current treatments to attenuate myocardial stress during reperfusion damage show limited success. This is largely due to insufficient knowledge about the pathogenic mechanisms underlying cardiac I/R injury, which include protein oxidative modification, DNA damage, endoplasmic reticulum (ER) dysfunction, cell membrane rupture, mitochondrial apoptosis, ATP stress, cellular calcium overload, and cardiomyocyte necroptosis.

Over the last two decades, specialized structures called mitochondria-ER contact sites (MERCs) have been identified as critical regulators of cellular homeostasis by controlling tethering dynamics and Ca\(^{2+}\) transfer between the two organelles [4, 9]. Under physiological conditions, regulated Ca\(^{2+}\) transfer from ER to mitochondria promotes oxidative phosphorylation (OXPHOS) and sustains mitochondrial bioenergetics by stimulating the synthesis of ATP [10, 11]. Under pathological conditions, however, abnormal mitochondrial calcium overload induces the opening of the
mitochondrial permeability transition pore (mPTP), a mitochondria-regulated cell death pathway [12, 13]. Moreover, the mitochondrial-ER interaction also influences mitochondrial ROS production, which constitutes a main trigger of oxidative stress upon excess generation secondary to dysregulated activity of mitochondrial respiratory complexes and impaired OXPHOS [14, 15]. Furthermore, abnormal ER-mitochondria interaction impairs mitochondrial morphology and turnover, affecting normal fission/fusion cycles, and reduces mitochondrial membrane potential (MMP) to precipitate mitochondrial failure [16–18]. Interestingly, ER homeostasis is also compromised by deficiencies in MERCs, giving rise to ER dysfunction and the ensuing abnormal protein adaptive response [19–22]. Still, despite its potential significance for cardioprotection, the role of mitochondria-ER interaction during myocardial posts ischemic reperfusion damage remains incompletely understood.

Several cardioprotective drugs, including endogenous and natural compounds, have been successfully tested in mouse models of cardiac I/R injury [23–26]. Melatonin is widely used for the treatment of insomnia and sleep disorders undergoing different medical conditions. Notably, recent studies have reported the cardioprotective effects of melatonin in various cardiovascular disorders [27–32]. For example, preclinical data showed that melatonin alleviates hyperglycemia-mediated cardiomyocyte damage through improving Sirt6-dependent mitochondrial quality control [33] and attenuates myocardial infarction by stimulating cardiomyocyte proliferation via the miRNA-regulated Ctnnd1 pathway [34]. Melatonin was shown to reduce the incidence of myocardial damage in Alzheimer’s disease through modulation of cGAS-STING-TBK1-mediated mitophagy [35] and to inhibit abnormal calcium accumulation in aortic valve through the circ-RNA-mediated-DPP4 pathway [36]. Although ample evidence supports the beneficial impact of melatonin on myocardial posts ischemic reperfusion damage, the influence of melatonin on mitochondria-ER interaction has not been investigated. Based on this, we set experiments to illuminate whether melatonin reduces cardiac I/R injury through normalization of MERCs.

2. Materials and Methods

2.1. Cell Culture, H/R Protocol, and Melatonin Treatment. H9C2 cells were obtained from Lonza, Allendale, NJ, USA (Cat. No.: CC-2527), and used for all cell experiments. H9C2 cells were maintained in DMEM high-glucose medium (Cat. No.: CC-2527), and used for all cell experiments. H9C2 cells were obtained from Lonza, Allendale, NJ, USA.

2.2. qPCR for mRNA Expression Detection. Total RNA was isolated using TRIzol reagent (ThermoFisher Scientific, Cat No. 15596026). RNA was quantified, and quality was determined by using BioDrop (Biochrom, UK) [39, 40]. Total RNA (1 μg) was reverse transcribed and real-time PCR analysis using Fast SYBR® Green Master Mix (Applied Biosys-

tems, Cat No. 4385612) [41], and each measurement was carried out in duplicate through a CFX384 real time on Applied Biosystems QuantStudio Real-Time PCR Systems [42, 43]. The expression level was normalized to GAPDH, and three independent amplifications were performed for each sample in each technique [44, 45].

2.3. Mitochondrial Potential Observation and Adenosine Triphosphate (ATP) Detection. Mitochondrial potential was observed through immunofluorescence using a JC-1 mitochondrial potential assay kit (C2006, Beyotime, Shanghai, China) [46, 47]. Adenosine triphosphate (ATP) production was detected as previously described using an ATP fluorometric assay kit (K354, BioVision, Milpitas, CA, USA) [48].

2.4. IP3R Overexpression. H9C2 cells were transfected at passage 4-6 using Santa Cruz transfection reagent or Amaxa electroporation as described [49, 50]. One day before transfection, the media were changed to an antibiotic-free medium. Transfection of IP3R adenovirus (IP3R/Ad) was carried out using Lipofectamine 2000 [51].

2.5. Mitochondrial Complex Activity Measurements. Mitochondrial complex I enzyme activity was determined using a microplate colorimetric assay kit (ab109721, Abcam, Cambridge, MA, USA) with purified mitochondria (ab110168, Abcam) [52]. Data were presented as fold alteration relative to control [53].

2.6. Cell Viability Assay. MTT for cell viability analysis is based on the fact that dimethyl sulfoxide (DMSO) can dissolve water-insoluble blue purple crystal formazan in cells which was generated by exogenous MTT to water-insoluble blue purple crystal formazan [54, 55]. The optical absorption value of formazan was further measured at 490 nm wavelength by microplate analyzer. According to the measured absorbance value (OD value), the number of living cells can be judged [56].

2.7. Immunofluorescence. H9C2 cells were cultured with ice-cold 4% paraformaldehyde (PFA) solution. Blocking was conducted using 5% normal goat serum supplemented with 1% bovine serum albumin in TBS (0.2 M Tris base, 1.5 M NaCl) for 2 h at room temperature. For vWF staining, cell sections were incubated with antibody overnight. Sections were washed and incubated with Alexa-Fluor 594 secondary Dronkey anti-Sheep antibody at a dilution of 1:250 (ThermoFisher Scientific, Cat No. A-10106) at room temperature for 1 h [57]. Then, we used anti-GFP antibody at a dilution of 1:50 (Abcam, rabbit polyclonal antibody Cat No. ab6556) followed by secondary goat anti-rabbit IgG, Alexa Flour-488 at dilution 1:200 (ThermoFisher Scientific, Cat No. R37116) to stain samples. DAPI (ThermoFisher Scientific, Cat No. D-1306) at dilution 1:1000 was used for nuclei staining [58]. The results were collected under an inverted laser scanning confocal microscope. Representative images shown in the figures were selected to most accurately match the quantitative analysis. Regions were selected randomly to avoid biasing [59].

2.8. Western Blot Analysis. H9C2 cells were pelleted and lysed in IP buffer complemented with a protease and phosphatase
inhibitor cocktail (ThermoFisher) [60]. Proteins were separated by 4-10% standard SDS-polyacrylamide gel electrophoresis and were transferred electrophoretically onto a PVDF membrane using Trans-Blot Turbo Transfer system (Bio-Rad) [61]. Blots were probed with polyclonal antibodies overnight at 4°C. Clathrin (BD Biosciences) was used as an endogenous control. A chemiluminescence reagent was used to develop the images [62]. The density of the target protein band was normalized to GAPDH. Each experiment was repeated three times [63].

Figure 1: Melatonin attenuates H/R-mediated mitochondrial damage in cardiomyocytes. Cardiomyocytes were subjected to H/R in the presence or absence of melatonin. (a, b) Assessment of mitochondrial ROS production in H9C2 cells. (c, d) Evaluation of MMP through JC-1 staining. (e) Analysis of mPTP opening rate. (f) Fluorimetric ATP production assay results. *p < 0.05.
2.9. Statistical Analysis. The statistical analyses were performed using GraphPad Prism version 8.0. We assume normality for all the tests relying on the central limit theorem. Normally distributed data were expressed as mean ± SD. \( p < 0.05 \) was considered statistically significant.

3. Results

3.1. Melatonin Attenuates Mitochondrial Damage in Cardiomyocytes Exposed to Hypoxia/Reoxygenation Injury. To mimic myocardial postischemic reperfusion damage in vivo, cultured H9C2 cells were exposed to a 45 min hypoxia, 2-hour reoxygenation (H/R) protocol in the presence or absence of melatonin. Mitochondrial damage was then assessed by measuring ROS production in living cells. As shown in Figures 1(a) and 1(b), compared to normoxic control cells, increased mitochondrial ROS production was observed in H/R-treated cells. In contrast, H/R-evoked ROS augmentation was significantly attenuated in melatonin-treated cells. Similarly, another key parameter of mitochondrial function, namely, MMP, was significantly decreased by H/R injury and largely stabilized upon treatment with melatonin (Figures 1(c) and 1(d)). We also examined the effect of melatonin on mPTP opening, identified as an early marker of apoptotic/necrotic cell death. As shown in Figures 1(e), H/R exposure promoted mPTP opening and

![Figure 2: Melatonin reduces ER stress in cardiomyocytes exposed to H/R injury. (a, b) Analysis of CHOP and caspase-12 transcription levels by qPCR. (c–e) Immunofluorescent detection of CHOP and caspase-12 expressions. \( *p < 0.05 \).]
Figure 3: Continued.
this event was prevented by melatonin. Since cardiomyocyte contraction depends critically on mitochondrial ATP production, we next examined whether melatonin had an ability to prevent the loss of ATP induced by H/R. Compared to the control cells, ATP production was markedly suppressed due to H/R damage but preserved instead in melatonin-treated cardiomyocytes (Figure 1(f)). Our data showed that cardiomyocyte mitochondrial damage undergoing H/R injury can be attenuated by melatonin.

3.2. Melatonin Reduces Cardiomyocyte’s H/R-Mediated ER Stress. In addition to mitochondrial damage, ER stress or dysfunction represents a primary event during H/R-mediated cardiomyocyte injury. Therefore, and based on the above findings, we assessed the impact of melatonin with a focus on the activity of ER stress markers following exposure of H9C2 cells to H/R. Compared with the normoxic group, the activities of CHOP, ATF6, and caspase-12 mRNA were upregulated after H/R, whereas melatonin exposure abrogated this effect (Figures 2(a) and 2(b)). The anti-ER stress actions of melatonin during cardiomyocyte H/R damage was further confirmed by CHOP and caspase-12 immunofluorescence (Figures 2(c)–2(e)). These data showed that melatonin alleviates ER stress in H/R-treated cardiomyocytes.

3.3. Melatonin Stabilizes Mitochondria-ER Contact Sites in H/R-Challenged Cardiomyocytes. Since physical interaction between mitochondria and ER membranes critically impacts mitochondrial function and ER homeostasis, we next explored whether melatonin’s protective actions against cardiomyocyte H/R injury involve stabilization of MERCS. Results from qPCR assays illustrated that several MERCS genes, namely, Fis1, BAP31, Mfn2, and IP3R, were rapidly augmented after H/R injury. However, these changes were virtually abolished in cardiomyocytes treated with melatonin (Figures 3(a)–3(d)), an effect further supported by protein quantity analysis (Figures 3(e)–3(i)). These data showed that melatonin counteracts the deleterious effects of H/R on mitochondria-ER tethering domains by modulating the expression of key MERCS genes.

3.4. Overexpression of IP3R Abolishes Melatonin-Mediated Mitochondrial Protection. To assess whether stabilization of mitochondria-ER interaction is required for melatonin-mediated protection against H/R-induced mitochondrial failure in cardiomyocytes, IP3R overexpression assay was performed due to a critical role of IP3R in Ca\(^{2+}\) transferring from the ER to mitochondria. As illustrated in Figures 4(a)
and 4(b), after IP3R overexpression mitochondrial ROS overloading occurred in H/R-challenged, melatonin-treated cardiomyocytes. Similarly, after H/R exposure, melatonin failed to sustain both MMP (Figures 4(c) and 4(d)) and ATP production (Figure 4(e)) in IP3R-overexpressing cardiomyocytes. These results suggest that melatonin mediates mitochondrial protection by preventing H/R-mediated IP3R upregulation at MERCS.

Figure 4: Overexpression of IP3R abolishes melatonin-mediated mitochondrial protection. IP3R adenovirus (IP3R/Ad) was transfected into cardiomyocytes to overexpress IP3R prior to H/R. (a, b) Assessment of mitochondrial ROS production. (c, d) Determination of MMP variations in H9C2 cells stained with JC-1. (e) ATP production assay results. *p < 0.05.
3.5. IP3R Overexpression Reduces Melatonin-Mediated Protection against ER Stress. To assess a potential impact mitochondria-ER interaction in melatonin-mediated protection against H/R-induced ER stress, the activity of ER stress-related factor was evaluated in IP3R-overexpressing cardiomyocytes. As shown in Figures 5(a) and 5(b), the suppressive action of melatonin on H/R-upregulated CHOP and caspase-12 transcription was nullified in cardiomyocytes overexpressing IP3R. Once again, this effect was confirmed at the protein level through western blot assays (Figures 5(c)–5(e)). These data suggest that IP3R overexpression offsets the protective action of melatonin on ER homeostasis in H/R-attacked cardiomyocytes.

4. Discussion

The present study suggests a previously unrecognized beneficial action of melatonin in myocardial postischemic reperfusion damage. We found that melatonin normalizes mitochondria-ER interaction, resulting in improved...
mitochondrial function and decreased ER stress. Specifically, our data showed that melatonin suppresses H/R-mediated IP3R overexpression and thus sustains MMP, inhibits mitochondrial ROS production, and preserves ATP production in H/R-exposed, cultured cardiomyocytes. Although confirmatory analyses of Ca2+ fluxes are warranted, our data suggest that melatonin alleviates H/R-mediated ER dysfunction/stress and mitochondrial failure through inhibition of IP3R-mediated mitochondrial Ca2+ overload. This finding suggests a novel cardioprotective mechanism mediated by melatonin in cardiac I/R injury, which may be relevant for treatment strategies focusing on modulation of mitochondria-ER interaction upon acute myocardial reperfusion injury.

The role of mitochondria-ER contact in cardiovascular disorders has been widely described [64, 65]. For example, cardiac hypoxia promotes the activation of mitochondrial ubiquitin ligase (MITOL/MARCH5), a MERCS-associated protein, leading to mitochondrial ubiquitination and degradation and eventually to myocardial cell death [66]. In the pathogenesis of sepsis-induced cardiomyopathy, melatonin is able to maintain mitochondrial behavior and ER shape through inhibiting receptor-interacting protein kinase 3 (RIPK3), a key controller of necroptosis [67]. Alterations in mitochondria-ER tethering and communication pathways can lead to mitochondrial calcium accumulation and redox imbalance, which have been implicated into impaired cardiac contract [68]. In turn, abnormal IP3-controlled Ca2+ transfer from ER to mitochondria contributes to cardiac insulin resistance and myocardial fibrosis in the development of diabetic cardiomyopathy [69, 70]. The present data further validate the role of mitochondria-ER contact on cardiomyocyte function, suggesting a promising target when development of effective approaches to manage cardiovascular disorders. We provide evidence that melatonin acts as an upstream regulator of mitochondria-ER interaction, stabilizing MERCS and thus reducing I/R-related cardiomyocyte damage. Although previous studies highlighted the cardioprotective outcome of melatonin during myocardial reperfusion, hypertension, and vascular diseases, this is, to our knowledge, the first study to investigate the influence of melatonin on mitochondria-ER interaction in an in vitro model of myocardial reperfusion damage. While further experiments are required to confirm our observations, our findings suggest that melatonin administration might be an effective approach to restore proper mitochondria-ER communication in myocardial reperfusion attack [71].

The cardioprotective action of melatonin has been widely described. For example, melatonin delivery significantly alleviates postinfarction cardiac remodeling through regulation of a JNK/p53-dependent mechanism in diabetic mice [72, 73]. Mitochondrial biogenesis is improved by melatonin treatment during cardiac I/R injury, and this effect promotes mitochondrial turnover as well as cardiomyocyte survival [22]. Cardiac microvascular injury in the reperfused heart, an often neglected topic in the field of cardiac I/R injury, was shown to be attenuated by melatonin through inhibition of Ripk3-mediated necroptosis [28]. In a model of LPS-related cardiac dysfunction, melatonin treatment reduced cardiomyocyte death by sustaining mitochondrial function through a mechanism involving the Mst1-JNK pathway [74, 75]. Platelet hyperreactivity has been associated with the occurrence of myocardial damage and cardiac decompensation. Interestingly, in a cardiac I/R injury mouse model, melatonin treatment was shown to inhibit platelet activation by improving PPARy contents and hence repressing the FUNDC1-controlled mitochondrial autophagy pathway in platelets [27]. Herein, our data confirmed that melatonin inhibits in cardiomyocytes with the H/R-mediated upregulation of IP3R, which acts as a calcium channel in the surface of the ER. Increased IP3R expression promotes calcium leakage from ER into the mitochondria; in turn, excess intramitochondrial calcium activates the mitochondria-dependent cell death program, leading to cardiomyocyte apoptosis or necrosis. Of note, we found that the H/R-mediated upregulation of other mitochondria-ER contact markers, namely, Fis1, BAP31, and Mfn2, was also inhibited by melatonin. However, additional data are required to clarify whether cardiomyocyte viability and function are affected by melatonin’s effects on these proteins.

In conclusion, our data demonstrate that melatonin treatment attenuates H/R-mediated cardiomyocyte damage in vitro. Application of melatonin inhibits the expression of IP3R and thus normalizes the interaction between mitochondria and ER, resulting into improved mitochondrial function and decreased ER stress. Although additional animal experiments are necessary to further elucidate the molecular actions of melatonin on cardiomyocytes, this finding may provide a potential target for clinical treatment of cardiac I/R injury. Of note, our study may also be relevant for devising strategies to alleviate cellular and organ dysfunction associated with aging and age-related diseases, which are known to be critically influenced by alterations in MERCS.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors have no conflicts of interest to declare regarding the present manuscript.

**Authors’ Contributions**

Wenya Li, Botao Liu, and Jia Zheng designed and performed experiments and analyzed the data. Lin Wang and Jiliu Liu performed experiments. Xiuhui Yang and Jia Zheng collected the specimens. Wenya Li and Jia Zheng designed and performed the manuscript. All authors read and approved the final version of the manuscript prior to submission.

**References**

[1] H. Zhou, S. Toan, P. Zhu, J. Wang, J. Ren, and Y. Zhang, “DNA-PKcs promotes cardiac ischemia reperfusion injury through mitigating BI-1-governed mitochondrial homeostasis,” Basic Research in Cardiology, vol. 115, no. 2, p. 11, 2020.
[2] G. Heusch, “Coronary microvascular obstruction: the final frontier in cardioprotection,” Basic Research in Cardiology, vol. 114, no. 6, p. 45, 2019.

[3] D. J. Hausenloy, M. Ntskehe, and D. M. Yellon, “A future for remote ischaemic conditioning in high-risk patients,” Basic Research in Cardiology, vol. 115, no. 3, p. 35, 2020.

[4] W. E. Hughes, A. M. Beyer, and D. D. Gutterman, “Vascular autophagy in health and disease,” Basic Research in Cardiology, vol. 115, no. 4, p. 41, 2020.

[5] I. Cuijpers, S. J. Simmonds, M. van Bilsen et al., “The role of mitochondria in cardioprotection,” Basic Research in Cardiology, vol. 10, no. 1, pp. 39–20, 2020.

[6] J. Wang, S. Toan, and H. Zhou, “New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury,” Angiogenesis, vol. 23, no. 3, pp. 299–314, 2020.

[7] J. Wang and H. Zhou, “Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia – reperfusion injury,” Acta Pharmacologica Sinica B, vol. 10, no. 10, pp. 1866–1879, 2020.

[8] J. Wang, P. Zhu, R. Li, J. Ren, Y. Zhang, and H. Zhou, “Bax inhibitor 1 preserves mitochondrial homeostasis in acute kidney injury through promoting mitochondrial retention of PHB2,” Theranostics, vol. 10, no. 1, pp. 384–397, 2020.

[9] M. Yang, C. Li, S. Yang et al., “Mitochondria-associated ER membranes-the origin site of autophagy,” Frontiers in Cell and Development Biology, vol. 8, p. 595, 2020.

[10] E. L. Wilson and E. Metzakopian, “ER-mitochondria contact sites in neurodegeneration: genetic screening approaches to investigate novel disease mechanisms,” Cell Death and Differentiation, vol. 28, no. 6, pp. 1804–1821, 2020.

[11] H. Jiang, D. Jia, B. Zhang et al., “Exercise improves cardiac function and glucose metabolism in mice with experimental myocardial infarction through inhibiting HDAC4 and upregulating GLUT1 expression,” Basic Research in Cardiology, vol. 115, no. 3, p. 28, 2020.

[12] C. Li, L. Li, M. Yang, L. Zeng, and L. Sun, “PACS-2: a key regulator of mitochondria-associated membranes (MAMs),” Pharmacological Research, vol. 160, p. 105080, 2020.

[13] J. Wang, P. Zhu, R. Li, J. Ren, and H. Zhou, “Fundc1-dependent mitophagy is obligatory to ischemic preconditioning–conferring renoprotection in ischemic AKI via suppression of Drp1-mediated mitochondrial fission,” Redox Biology, vol. 30, p. 101415, 2020.

[14] A. Gil-Hernández and A. Silva-Palacios, “Relevance of endoplasmic reticulum and mitochondria interactions in age-associated diseases,” Ageing Research Reviews, vol. 64, p. 101193, 2020.

[15] H. Zhou, P. Zhu, J. Wang, S. Toan, and J. Ren, “DNA-PKcs promotes alcohol-related liver disease by activating Drp1-related mitochondrial fission and repressing FUNDCl1-required mitophagy,” Signal Transduction and Targeted Therapy, vol. 4, no. 1, p. 56, 2019.

[16] D. Kundu and R. Pasrija, “The ERMES (endoplasmic reticulum and mitochondria encounter structures) mediated functions in fungi,” Mitochondrion, vol. 52, pp. 89–99, 2020.

[17] Q. Ma, R. J. Reiter, and Y. Chen, “Role of melatonin in controlling angiogenesis under physiological and pathological conditions,” Angiogenesis, vol. 23, no. 2, pp. 91–104, 2020.

[18] C. Margadant, “Positive and negative feedback mechanisms controlling tip/stalk cell identity during sprouting angiogenesis,” Angiogenesis, vol. 23, no. 2, pp. 75–77, 2020.

[19] M. Wallert, M. Ziegler, X. Wang et al., “α-Tocopherol preserves cardiac function by reducing oxidative stress and inflammation in ischemia/reperfusion injury,” Redox Biology, vol. 26, p. 101292, 2019.

[20] Y. H. Zuo, Y. B. Liu, C. S. Cheng et al., “Isovalerylbinankadinur A ameliorates cardiac ischemia/reperfusion injury through activating GR dependent RISK signaling,” Pharmacological Research, vol. 158, p. 104897, 2020.

[21] J. Jian, P. Zhang, Y. Li et al., “Reprogramming of miR-181a/DNA methylation patterns contribute to the maternal nicotine exposure-induced fetal programming of cardiac ischemia-sensitive phenotype in postnatal life,” Theranostics, vol. 10, no. 25, pp. 11820–11836, 2020.

[22] X. Qi and J. Wang, “Melatonin improves mitochondrial biogenesis through the AMPK/PGC1α pathway to attenuate ischemia/reperfusion-induced myocardial damage,” Aging (Albany NY), vol. 12, no. 8, pp. 7299–7312, 2020.

[23] J. Zhang, X. Cai, Q. Zhang et al., “Hydrogen sulfide restores sevoflurane postconditioning mediated cardioprotection in diabetic rats: role of SIRT1/Nrf2 signaling-modulated mitochondrial dysfunction and oxidative stress,” Journal of Cellular Physiology, vol. 236, no. 7, pp. 5052–5068, 2021.

[24] M. Kohlhuber, V. R. Pell, N. Burger et al., “Protection against cardiac ischemia-reperfusion injury by hypothermia and by inhibition of succinate accumulation and oxidation is additive,” Basic Research in Cardiology, vol. 114, no. 3, p. 18, 2019.

[25] T. Alakoski, J. Ulvila, R. Yrjölä et al., “Inhibition of cardiomyocyte Sprouty1 protects from cardiac ischemia-reperfusion injury,” Basic Research in Cardiology, vol. 114, no. 2, p. 7, 2019.

[26] C. Xiao, M. L. Xia, J. Wang et al., “Luteolin attenuates cardiac ischemia/reperfusion injury in diabetic rats by modulating Nrf2 antioxidative function,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 2719252, 9 pages, 2019.

[27] H. Zhou, D. Li, P. Zhu et al., “Melatonin suppresses platelet activation and function against cardiac ischemia/reperfusion injury via PPARγ/FUNDCl/mitophagy pathways,” Journal of Pineal Research, vol. 63, no. 4, 2017.

[28] H. Zhou, D. Li, P. Zhu et al., “Inhibitory effect of melatonin on necroptosis via repressing the Ripk3-PGAM5-Cypl-dMPTP pathway attenuates cardiac microvascular ischemia–reperfusion injury,” Journal of Pineal Research, vol. 65, no. 3, article e12503, 2018.

[29] H. Zhou, Q. Ma, P. Zhu, J. Ren, R. J. Reiter, and Y. Chen, “Protective role of melatonin in cardiac ischemia-reperfusion injury: from pathogenesis to targeted therapy,” Journal of Pineal Research, vol. 64, no. 3, 2018.

[30] H. Zhou, Y. Zhang, S. Hu et al., “Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission–VDAC1-HK2-mPTP pathway,” Journal of Pineal Research, vol. 63, no. 1, p. e12413, 2017.

[31] H. Zhou, J. Wang, P. Zhu, S. Hu, and J. Ren, “Ripk3 regulates cardiac microvascular reperfusion injury: The role of IP3R-dependent calcium overload, XO-mediated oxidative stress and F-action/filopodia-based cellular migration,” Cell Signal, vol. 45, pp. 12–22, 2018.
[32] H. Zhou, Y. Yue, J. Wang, Q. Ma, and Y. Chen, “Melatonin therapy for diabetic cardiomyopathy: a mechanism involving Syk- mitochondrial complex 1-SERCA pathway,” Cellular Signalling, vol. 47, pp. 88–100, 2018.

[33] L. M. Yu, X. Dong, X. D. Xue et al., “Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia-reperfusion injury by improving mitochondrial quality control: role of SIRT6,” Journal of Pineaal Research, vol. 70, no. 1, article e12698, 2021.

[34] W. Y. Ma, R. J. Song, B. B. Xu et al., “Melatonin promotes cardiomyocyte proliferation and heart repair in mice with myocardial infarction via miR-143-3p/Yap/Cttnnd1 signaling pathway,” Acta Pharmacologica Sinica, vol. 42, no. 6, pp. 921–931, 2020.

[35] S. Wang, L. Wang, X. Qin et al., “ALDH2 contributes to melanin-induced protection against APP/PS1 mutation-promoted cardiac anomalies through cGAS-STING-TBK1-mediated regulation of mitophagy,” Signal Transduction and Targeted Therapy, vol. 5, no. 1, p. 119, 2020.

[36] W. R. Chen, Y. J. Zhou, Y. Sha, X. P. Wu, J. Q. Yang, and F. Liu, “Melatonin attenuates vascular calcification by inhibiting mitochondria fission via an AMPK/Drp1 signalling pathway,” Journal of Cellular and Molecular Medicine, vol. 24, no. 11, pp. 6043–6054, 2020.

[37] E. H. Moon, Y. H. Kim, P. N. Vu et al., “TMEM100 is a key factor for specification of lymphatic endothelial progenitors,” Angiogenesis, vol. 23, no. 3, pp. 339–355, 2020.

[38] V. Selvaraju, M. Thirunavukkarasu, M. Joshi et al., “Deletion of newly described pro-survival molecule Pellino-1 increases oxidative stress, downregulates cIAP2/NF-κB cell survival response, reduces angiogenic response, and thereby aggravates tissue function in mouse ischemic models,” Basic Research in Cardiology, vol. 115, no. 4, p. 45, 2020.

[39] M. T. Islam, “Angiostatic effects of ascorbic acid: current status and future perspectives,” Angiogenesis, vol. 23, no. 3, pp. 275–277, 2020.

[40] J. Lyu, M. Wang, X. Kang et al., “Macrophage-mediated regulation of catecholamines in sympathetic neural remodeling after myocardial infarction,” Basic Research in Cardiology, vol. 115, no. 5, p. 56, 2020.

[41] M. Giovarelli, S. Zecchini, E. Martini et al., “Drp1 overexpression induces desmin disassembly and drives kinesin-1 activation promoting mitochondrial trafficking in skeletal muscle,” Cell Death and Differentiation, vol. 27, no. 8, pp. 2383–2401, 2020.

[42] L. Du, J. Wang, Y. Chen et al., “Novel biphenyl diester derivative AB-38h inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy,” Cell Biology and Toxicology, vol. 36, no. 3, pp. 243–260, 2020.

[43] A. Sanchez, M. Kuras, J. R. Murillo et al., “Novel functional proteins coded by the human genome discovered in metastases of melanoma patients,” Cell Biology and Toxicology, vol. 36, no. 3, pp. 261–272, 2020.

[44] C. L. Depoix, A. Colson, C. Hubinont, and F. Debieve, “Impaired vascular endothelial growth factor expression and secretion during in vitro differentiation of human primary term caytophoblasts,” Angiogenesis, vol. 23, no. 2, pp. 221–230, 2020.

[45] L. Jiang and N. Li, “B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy,” Angiogenesis, vol. 23, no. 4, pp. 515–529, 2020.

[46] S. Liu, J. Chen, J. Shi et al., “M1-like macrophage-derived exosomes suppress angiogenesis and exacerbate cardiac dysfunction in a myocardial infarction microenvironment,” Basic Research in Cardiology, vol. 115, no. 2, p. 22, 2020.

[47] M. Lindner, H. Mehel, A. David et al., “Fibroblast growth factor-23 decreases PDE4 expression in heart increasing the risk of cardiac arrhythmia; Klotho opposes these effects,” Basic Research in Cardiology, vol. 115, no. 5, p. 51, 2020.

[48] C. Lugassy, H. K. Kleinman, P. B. Vermeulen, and R. L. Barnhill, “Angiotropism, pericytic mimicry and extravascular migratory metastasis: an embryogenesis-derived program of tumor spread,” Angiogenesis, vol. 23, no. 1, pp. 27–41, 2020.

[49] B. L. Jensen, “The enzyme L-arginase type 2 in proximal tubular epithelium links urea accumulation and protection against ischemic insults in kidney,” Acta Physiologica, vol. 229, no. 3, article e13489, 2020.

[50] E. Singh, R. E. Redgrave, H. M. Phillips, and H. M. Arthur, “Arterial endoglin does not protect against arteriovenous malformations,” Angiogenesis, vol. 23, no. 4, pp. 559–566, 2020.

[51] K. Qiao, Y. Liu, Z. Xu et al., “RNA m6A methylation promotes the formation of vasculogenic mimicry in hepatocellular carcinoma via Hippo pathway,” Angiogenesis, vol. 24, no. 1, pp. 83–96, 2020.

[52] D. Song, L. Tang, L. Wang et al., “Roles of TGFβ1 in the expression of phosphoinositide 3-kinase isoform genes and sensitivity and response of lung telocytes to PI3K inhibitors,” Cell Biology and Toxicology, vol. 36, no. 1, pp. 51–64, 2020.

[53] E. Steffen, W. B. E. Mayer Von Wittgenstein, M. Hennig et al., “Murine sca1/lk1-positive cells are not endothelial progenitor cells, but B2 lymphocytes,” Basic Research in Cardiology, vol. 115, no. 2, p. 18, 2020.

[54] Q. Jin, R. Li, N. Hu et al., “DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mif- required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways,” Redox Biology, vol. 14, pp. 576–587, 2018.

[55] P. Zhu, S. Hu, Q. Jin et al., “Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: a mechanism involving calcium overload/XY/ROS/mPTP pathway,” Redox Biology, vol. 16, pp. 157–168, 2018.

[56] C. H. Tsai, Y. Lee, C. H. Li, Y. W. Cheng, and J. J. Kang, “Down-regulation of aryl hydrocarbon receptor intensifies carcinogen-induced retinal lesion via SOCS3-STAT3 signaling,” Cell Biology and Toxicology, vol. 36, no. 3, pp. 223–242, 2020.

[57] Y. Yang, L. Ma, C. Wang et al., “Matrix metalloproteinase-7 in platelet-activated macrophages accounts for cardiac remodeling in uremic mice,” Basic Research in Cardiology, vol. 115, no. 3, p. 30, 2020.

[58] Q. K. Yang, T. Chen, S. Q. Wang, X. J. Zhang, and Z. X. Yao, “Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself,” Angiogenesis, vol. 23, no. 3, pp. 279–298, 2020.

[59] A. Wincewicz and P. Woltanowski, “Leopold Auerbach’s achievements in the field of vascular system,” Angiogenesis, vol. 23, no. 4, pp. 577–579, 2020.

[60] A. Umapathy, L. W. Chamley, and J. L. James, “Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies,” Angiogenesis, vol. 23, no. 2, pp. 105–117, 2020.
H. Wang, A. Ramshekar, E. Kunz, D. B. Sacks, and M. E. Hartnett, "IQGAP1 causes choroidal neovascularization by sustaining VEGFR2-mediated Rac1 activation," *Angiogenesis*, vol. 23, no. 4, pp. 685–698, 2020.

N. N. Nazipova and S. A. Shabalina, "Understanding off-target effects through hybridization kinetics and thermodynamics," *Cell Biology and Toxicology*, vol. 36, no. 1, pp. 11–15, 2020.

Y. Tomita, B. Cakir, C. H. Liu et al., "Free fatty acid receptor 4 activation protects against choroidal neovascularization in mice," *Angiogenesis*, vol. 23, no. 3, pp. 385–394, 2020.

H. Zhou, S. Wang, S. Hu, Y. Chen, and J. Ren, "ER-mitochondria microdomains in cardiac ischemia-reperfusion injury: a fresh perspective," *Frontiers in Physiology*, vol. 9, p. 755, 2018.

A. Silva-Palacios, C. Zazueta, and J. Pedraza-Chaverri, "ER membranes associated with mitochondria: possible therapeutic targets in heart-associated diseases," *Pharmacological Research*, vol. 156, p. 104758, 2020.

L. Lu, J. Ma, J. Tang et al., "Irisin attenuates myocardial ischemia/reperfusion-induced cardiac dysfunction by regulating ER-mitochondria interaction through a mitochondrial ubiquitin ligase-dependent mechanism," *Clinical and Translational Medicine*, vol. 10, no. 5, article e166, 2020.

J. Zhong, Y. Tan, J. Lu et al., "Therapeutic contribution of melatonin to the treatment of septic cardiomyopathy: a novel mechanism linking Ripk3-modified mitochondrial performance and endoplasmic reticulum function," *Redox Biology*, vol. 26, p. 101287, 2019.

V. Eisner, G. Csordás, and G. Hajnóczky, "Interactions between sarco-endoplasmic reticulum and mitochondria in cardiac and skeletal muscle - pivotal roles in Ca2+ and reactive oxygen species signaling," *Journal of Cell Science*, vol. 126, Part 14, pp. 2965–2978, 2013.

M. Dia, L. Gomez, H. Thibault et al., "Reduced reticulum-mitochondria Ca2+ transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy," *Basic Research in Cardiology*, vol. 115, no. 3, p. 74, 2020.

P. Szaraz, P. Mander, N. Gasner, M. Librach, F. Iqbal, and C. Librach, "Glucose withdrawal induces Endothelin 1 release with significant angiogenic effect from first trimester (FTM), but not term human umbilical cord perivascular cells (HUCPVC)," *Angiogenesis*, vol. 23, no. 2, pp. 131–144, 2020.

J. Martínez-Milla, C. Galán-Arriola, M. Carnero et al., "Translational large animal model of hibernating myocardium: characterization by serial multimodal imaging," *Basic Research in Cardiology*, vol. 115, no. 3, p. 33, 2020.

L. Lu, J. Ma, M. Sun et al., "Melatonin ameliorates MI-induced cardiac remodeling and apoptosis through a JNK/p53-dependent mechanism in diabetes mellitus," *Oxidative Medicine and Cellular Longevity*, vol. 2020, Article ID 1535201, 14 pages, 2020.

R. Szulczech, G. Sanchez-Duffhues, N. Rol et al., "Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells," *Angiogenesis*, vol. 23, no. 4, pp. 699–714, 2020.

H. Ouyang, Q. Li, J. Zhong et al., "Combination of melatonin and irisin ameliorates lipopolysaccharide-induced cardiac dysfunction through suppressing the Mst1–JNK pathways," *Journal of Cellular Physiology*, vol. 235, no. 10, pp. 6647–6659, 2020.

B. Pflüger-Müller, J. A. Oo, J. Heering et al., "The endocannabinoid anandamide has an anti-inflammatory effect on CCL2 expression in vascular smooth muscle cells," *Basic Research in Cardiology*, vol. 115, no. 3, p. 34, 2020.